Top Page
4DMedical Ltd
(Sydney:4DX)
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
4DMedical Ltd Business Overview & Revenue Model
4DMedical Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.86M | 3.75M | 282.18K | 1.05M | 216.98K | 1.23M | Gross Profit |
| 5.48M | 3.52M | 248.03K | 280.62K | 125.13K | -8.13M | EBIT |
| -27.46M | -27.97M | -31.13M | -36.75M | -18.78M | -15.96M | EBITDA |
| -44.64M | -31.86M | -33.74M | -36.34M | -18.04M | -15.77M | Net Income Common Stockholders |
| -39.54M | -35.98M | -31.46M | -24.59M | -21.42M | -21.98M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 15.95M | 30.61M | 69.58M | 51.11M | 80.88M | 8.43M | Total Assets |
| 102.01M | 120.02M | 92.92M | 74.31M | 92.64M | 15.82M | Total Debt |
| 4.82M | 5.12M | 5.14M | 6.24M | 1.69M | 16.49M | Net Debt |
| -11.13M | -25.49M | -64.44M | -44.88M | -79.19M | 8.06M | Total Liabilities |
| 42.15M | 49.09M | 21.46M | 14.80M | 9.28M | 27.63M | Stockholders Equity |
| 59.86M | 70.93M | 71.46M | 59.51M | 83.36M | -11.81M |
| Cash Flow | Free Cash Flow | ||||
| -30.37M | -31.17M | -23.38M | -28.35M | -15.25M | -8.81M | Operating Cash Flow |
| -30.28M | -30.87M | -22.65M | -25.27M | -14.52M | -7.65M | Investing Cash Flow |
| -1.52M | -40.04M | -1.61M | -3.50M | -580.45K | -786.45K | Financing Cash Flow |
| -127.96K | 31.94M | 42.73M | -995.47K | 87.55M | 13.78M |
4DMedical Ltd Technical Analysis
4DMedical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $17.63B | 47.64 | 20.61% | 1.61% | 6.35% | 5.97% | |
69 Neutral | $118.21B | 28.37 | 15.38% | 1.70% | 8.00% | 9.09% | |
69 Neutral | $1.33B | 80.04 | 9.23% | ― | 10.79% | 5.20% | |
61 Neutral | AU$19.76M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
54 Neutral | AU$203.27M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
42 Neutral | AU$139.66M | ― | -52.37% | ― | 471.29% | -4.58% |
4DMedical Ltd Corporate Events
Olympus Corporation has launched a new campaign for SeleCT™ Screening in the United States, utilizing 4DMedical’s lung density analysis technology to identify candidates for the Olympus Spiration™ Valve System. This large-scale deployment of AI-based lung imaging marks a significant commercial expansion for 4DMedical, enhancing its clinical utility in early detection and therapy enablement. The partnership addresses the underdiagnosis of COPD, particularly emphysema, and expands 4DMedical’s presence in interventional respiratory care, offering substantial commercial growth opportunities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 5,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of an employee incentive scheme, indicating the company’s commitment to rewarding its workforce and potentially enhancing employee engagement and retention.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has issued nearly 15 million shares as part of the earnout consideration for its acquisition of Imbio Inc. This strategic move is expected to strengthen 4DMedical’s position in the healthcare industry, particularly in the field of lung health, by integrating Imbio’s capabilities and expanding its technological offerings.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 14,964,623 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, effective May 29, 2025. This move is part of a previously announced transaction and is expected to bolster the company’s market presence and provide additional capital for its ongoing operations and strategic initiatives.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has released an investor presentation providing a general overview of the company’s current activities and operations as of May 27, 2025. The presentation is informational and not intended as a financial product advice or an offer for securities, emphasizing the company’s commitment to transparency while highlighting legal restrictions on distribution, particularly in the United States.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has filed an FDA 510(k) submission for its CT:VQ™ software, a groundbreaking non-contrast CT-based lung imaging product that assesses both ventilation and perfusion in the lungs. This innovation addresses clinical and logistical challenges associated with traditional nuclear VQ imaging, offering higher resolution and accessibility by leveraging existing CT infrastructure. The company anticipates capturing the entire market of one million annual nuclear VQ scans in the U.S., with potential global market expansion. CT:VQ™ is expected to drive long-term growth in demand for lung assessments, transforming pulmonary care by making comprehensive evaluations more accessible, even in facilities without nuclear medicine capabilities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has secured a commercial contract with Intermountain Health, a prominent U.S. health system, for its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product. This contract, facilitated through a strategic partnership with Nuance Communications, marks the first major deployment of the PHA™ algorithm in a large health network, enhancing clinical decision-making and potentially expanding 4DMedical’s market presence. The agreement represents a significant opportunity for revenue growth as it transitions to full commercial terms, with plans to increase usage and expand to other products within the health system.
4DMedical Ltd has released its First 20 Investors Report, detailing the top investors holding significant shares in the company. The report reveals that the top 20 investors collectively hold 51.61% of the company’s issued capital, with CITICORP NOMINEES PTY LIMITED leading at 21.15%. This concentration of ownership among a few key investors could impact the company’s strategic decisions and market influence.
4DMedical Ltd has announced the application for quotation of new securities on the ASX, specifically options expiring on February 28, 2026. This move involves issuing listed options to participants of their recent SPP and placement, potentially enhancing the company’s capital structure and market presence.
4DMedical Limited announced that all resolutions proposed at its Extraordinary General Meeting were successfully passed. This outcome supports the company’s strategic initiatives, including the ratification of share issues and the approval of new options, which are expected to strengthen its financial position and operational capabilities. These developments are likely to enhance 4DMedical’s industry positioning and provide further value to its stakeholders.
4DMedical Limited reported a significant increase in operating revenue for the year-to-date FY2025, achieving a 103% rise compared to the previous period, with gross margins of 91.4%. The company is expanding its sales pipeline and has secured key contracts, including a renewal with the Cleveland Clinic and conversions of pilot programs into commercial contracts. A cost reduction program has been implemented, resulting in $6.5 million in annualized savings. The company is preparing for the FDA submission of its CT:VQ™ product, which has attracted interest from major medical centers and industry collaborators. Additionally, 4DMedical has received regulatory clearance for its CT LVAS™ in Canada and has been highlighted by Philips as a solution for improving veteran health outcomes.
4DMedical Ltd has announced the quotation of 131,498 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. These securities were issued as part of an employee incentive scheme and are not subject to transfer restrictions, indicating a strategic move to incentivize and retain talent within the company.
4DMedical Limited has lodged a supplementary prospectus with the Australian Securities and Investments Commission, amending the terms of its New Options and Piggyback Options offers. The company has streamlined the application process for eligible participants, who will automatically be deemed to have applied for their allocation unless they choose to opt out. This move aims to simplify participation and potentially increase stakeholder engagement in anticipation of future FDA clearance for its CT:VQ technology.
4DMedical Limited has announced a change in the address of its registry office in Sydney, effective from April 14, 2025. This move is part of the company’s ongoing efforts to streamline its operations and maintain compliance with ASX regulations. The change is not expected to impact the company’s operations or its stakeholders significantly, as contact details remain unchanged.
4DMedical Limited has successfully transitioned its pilot program with Integral Diagnostics into a commercial contract, marking a significant expansion of its lung imaging technology across Victoria, Australia. This development will enhance access to 4DMedical’s advanced diagnostic tools for general practitioners, respiratory specialists, and cardiologists, improving patient outcomes through more accurate and timely diagnoses of respiratory conditions. The contract signifies strong demand for 4DMedical’s innovative solutions and reinforces its commitment to revolutionizing lung health, further solidifying its commercial presence in the Australian market.
4DMedical Limited has secured two new contracts to supply its advanced lung imaging technology for clinical trials, one with SMS Biotech for a COPD stem cell therapy trial and another with an unnamed medical device developer. This highlights 4DMedical’s growing role in the respiratory health sector and its strategic partnerships aimed at advancing lung disease treatments. Additionally, 4DMedical’s technology was featured in a US Congressional testimony by Philips, emphasizing its potential to improve veteran healthcare outcomes through enhanced pulmonary diagnostics.
4DMedical Limited has announced an Extraordinary General Meeting scheduled for May 1, 2025, in Melbourne, Australia. The meeting will address several business matters, including the ratification of shares issued under a placement and the approval of new options. This meeting is significant for stakeholders as it involves key decisions impacting the company’s financial strategies and shareholder interests.
4DMedical Limited has announced a strategic review resulting in a cost reduction program expected to save $6.5 million annually. This initiative, alongside a successful $13.9 million capital raise, aims to optimize operational efficiency without impacting revenue growth or key milestones. The company is focusing on expanding its commercial activities, particularly in the US, and advancing its CT:VQ™ technology post-FDA clearance. Changes in company leadership include the appointment of Chris Cox as Interim CFO and Hamish George as Company Secretary. These measures are intended to safeguard the company’s long-term growth and financial stability.
4DMedical Ltd has announced a target market determination related to the issuance of new quoted options and piggyback options, which are tied to the company’s shares. These options are part of a prospectus set to be lodged in March 2025, aimed at institutional and sophisticated investors, eligible shareholders, and sub-underwriters. The options are designed to facilitate the trade of shares upon exercise, with the issuance subject to shareholder approval and ASX quotation requirements. This move is expected to enhance the company’s market positioning by potentially increasing share liquidity and attracting more investors.
4DMedical Ltd has announced a series of options offers, including SPP Options, Placement Options, Sub-Underwriter Options, and Piggyback Options, aimed at providing shareholders and eligible participants with opportunities to acquire new options. These offers are contingent upon obtaining shareholder approval under ASX Listing Rule 7.1. The initiative is part of the company’s strategic financial maneuvers to enhance its market position and provide value to its stakeholders.
4DMedical Limited has successfully completed an oversubscribed Securities Purchase Plan (SPP), raising $8.4 million, which, combined with a previous $5.5 million Placement, totals $13.9 million. These funds will support the company’s efforts to commercialize its lung diagnostics portfolio and advance the FDA submission of its CT:VQ™ technology. The capital raised positions 4DMedical to enhance its market presence and continue developing innovative respiratory diagnostic tools, benefiting shareholders and the broader healthcare industry.